RELATED CONTENT
NEWS
- US FDA panel backs Remicade use for ulcerative colitis in children
- Gilenya and Tasigna drive new product growth at Novartis
- NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
- First launch for edoxaban as eribulin also reaches the Japanese market

